Smithkline Beecham Corporation

Exelixis, Inc.

David Igo

Amarjit Sab Randhawa

Phillip William Waters

Daniel Patterson

Hilary Cannon

Paul R Johnson

David Leroy Carlton

Tri Tran

Om Parkash Dhingra

This invention relates to three crystalline forms of N-[3-fluoro-4-((6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl|oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide. Compound (I), designated as Form A, Form B, and Form C. The invention provides methods for treatment of cancer by exploiting the modulation of protein kinase activity. The invention also provides pharmaceutical compositions containing a crystalline form of Compound (I) and a pharmaceutically acceptable excipient. 

Crystalline Forms on N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

The present invention includes anhydrous crystalline forms of (2S,4S)-4-fluoro-1-[4-fluoro-&#x3b2;-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt.

[object Object]

A filtration assembly operable in connection with a crystal form screening workstation that provides for automated crystal form screening is disclosed. The assembly includes first and second valves, with each valve having an internal passage and first, second and third ports. A filter line is interposed between the first and second valves in fluid communication with the second port of the first valve and the second port of the second valve. A filter medium is in disposed in or at the end of the filter line and adapted to filter a drug-containing suspension flowing through the filter line. The filter medium is operable to filter fluids under both positive and negative pressure conditions.

High throughput crystal form screening workstation and method of use

Growing community of inventors

Durham, NC, United States of America

David Igo